NASDAQ: HCATHealth Catalyst Inc Stock
$4.47+0.01 (+0.22%)
Updated Mar 25, 2025
HCAT Price
$4.47
Fair Value Price
N/A
Market Cap
$313.84M
52 Week Low
$3.76
52 Week High
$9.24
P/E
-3.89x
P/B
0.86x
P/S
1.39x
PEG
N/A
Dividend Yield
N/A
Revenue
$306.58M
Earnings
-$69.50M
Gross Margin
45.9%
Operating Margin
-22.77%
Profit Margin
-22.7%
Debt to Equity
1.35
Operating Cash Flow
$15M
Beta
1.41
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
HCAT Overview
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is based in South Jordan, Utah.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine HCAT's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Health Information Service
Industry Rating
B
HCAT
Ranked#29 of 42
Ranked#29 of 42
Be the first to know about important HCAT news, forecast changes, insider trades & much more!
HCAT News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HCAT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HCAT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
HCAT is good value based on its book value relative to its share price (0.86x), compared to the US Health Information Services industry average (3.84x)
P/B vs Industry Valuation
HCAT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more HCAT due diligence checks available for Premium users.
Valuation
HCAT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.89x
Industry
15.74x
Market
32.24x
HCAT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.86x
Industry
3.84x
HCAT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HCAT's financial health
Profit margin
Revenue
$79.6M
Net Income
-$20.7M
Profit Margin
-26%
HCAT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
HCAT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$858.9M
Liabilities
$493.7M
Debt to equity
1.35
HCAT's short-term assets ($465.65M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HCAT's short-term assets ($465.65M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HCAT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
HCAT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.5M
Investing
-$112.7M
Financing
$37.7M
HCAT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
HCAT vs Health Information Service Stocks
Health Catalyst Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.